Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study

  • Quintero, E.
  • Carrillo, M.
  • Leoz, M.L
  • Cubiella, J.
  • Gargallo, C.
  • Lanas, A.
  • Bujanda, L.
  • Gimeno-García, A.Z.
  • Hernández-Guerra, M.
  • Nicolás-Pérez, D.
  • Alonso-Abreu, I.
  • Morillas, J.D.
  • Balaguer, F.
  • Muriel, A.
Background: First-degree relatives (FDR) of patients with colorectal cancer have a higher risk of developing colorectal cancer than the general population. For this reason, screening guidelines recommend colonoscopy every 5 or 10 y, starting at the age of 40, depending on whether colorectal cancer in the index-case is diagnosed at <60 or =60 y, respectively. However, studies on the risk of neoplastic lesions are inconclusive. The aim of this study was to determine the risk of advanced neoplasia (three or more non-advanced adenomas, advanced adenoma, or invasive cancer) in FDR of patients with colorectal cancer compared to average-risk individuals (i.e., asymptomatic adults 50 to 69 y of age with no family history of colorectal cancer). Methods and Findings: This cross-sectional analysis includes data from 8, 498 individuals undergoing their first lifetime screening colonoscopy between 2006 and 2012 at six Spanish tertiary hospitals. Of these individuals, 3, 015 were defined as asymptomatic FDR of patients with colorectal cancer (“familial-risk group”) and 3, 038 as asymptomatic with average-risk for colorectal cancer (“average-risk group”). The familial-risk group was stratified as one FDR, with one family member diagnosed with colorectal cancer at =60 y (n = 1, 884) or at <60 y (n = 831), and as two FDR, with two family members diagnosed with colorectal cancer at any age (n = 300). Multiple logistic regression analysis was used for between-group comparisons after adjusting for potential confounders (age, gender, and center). Compared with the average-risk group, advanced neoplasia was significantly more prevalent in individuals having two FDR with colorectal cancer (odds ratio OR] 1.90; 95% confidence interval CI] 1.36–2.66, p < 0.001), but not in those having one FDR with colorectal cancer diagnosed at =60 y (OR 1.03; 95% CI 0.83–1.27, p = 0.77) and <60 y (OR 1.19; 95% CI 0.90–1.58, p = 0.20). After the age of 50 y, men developed advanced neoplasia over two times more frequently than women and advanced neoplasia appeared at least ten y earlier. Fewer colonoscopies by 2-fold were required to detect one advanced neoplasia in men than in women. Major limitations of this study were first that although average-risk individuals were consecutively included in a randomized control trial, this was not the case for all individuals in the familial-risk cohort; and second, the difference in age between the average-risk and familial-risk cohorts. Conclusions: Individuals having two FDR with colorectal cancer showed an increased risk of advanced neoplasia compared to those with average-risk for colorectal cancer. Men had over 2-fold higher risk of advanced neoplasia than women, independent of family history. These data suggest that screening colonoscopy guidelines should be revised in the familial-risk population.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effect of oral anticoagulants on the outcome of faecal immunochemical test

  • Bujanda, L.
  • Sarasqueta, C.
  • Lanas, Á.
  • Quintero, E.
  • Cubiella, J.
  • Hernandez, V.
  • Morillas, J.D.
  • Perez-Fernández, T.
  • Salas, D.
  • Andreu, M.
  • Carballo, F.
  • Bessa, X.
  • Portillo, I.
  • Jover, R.
  • Balaguer, F.
  • Cosme, A.
  • Castells, A.
Background: We aimed to evaluate whether oral anticoagulants (OACs) alter faecal immunochemical test (FIT) performance in average-risk colorectal cancer (CRC) screening. Methods: Individuals aged 50–69 years were invited to receive one FIT sample (cutoff 75¿ng¿ml–1) between November 2008 and June 2011. Results: Faecal immunochemical test was positive in 9.3% (21 out of 224) of users of OAC and 6.2% (365 out of 5821) of non-users (P-trend=0.07). The positive predictive value (PPV) for advanced neoplasia (AN) in non-users was 50.4% vs 47.6% in users (odds ratio, 0.70; 95% CI, 0.3–1.8; P=0.5). The PPV for AN in OAC more antiplatelets (aspirin or clopidogrel) was 75% (odds ratio, 2; 95% CI, 0.4–10.8; P=0.4). Conclusions: Oral anticoagulant did not significantly modify the PPV for AN in this population-based colorectal screening program. The detection rate of advanced adenoma was higher in the combination OAC more antiplatelets.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial

  • Castells, Antoni
  • Quintero, Enrique
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Cubiella, Joaquín
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Akiko, Ono
  • Serra-Burriel, Miquel
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
  • Almazán, Raquel
  • Alonso-Abreu, Inmaculada
  • Banales, Jesús M.
  • Hernández, Vicent
  • Portillo, Isabel
  • Vanaclocha-Espí, Mercedes
  • Vega, Mariola de la
  • COLONPREV study investigators
Background: Colonoscopy and the faecal immunochemical test are accepted strategies for colorectal cancer screening in the average-risk population (ie, people aged ≥50 years without personal or family history of colorectal cancer). In this trial, we aimed to compare whether invitation to screening with faecal immunochemical test was non-inferior to colonoscopy in a screening programme. Methods: COLONPREV was a pragmatic, randomised, controlled, non-inferiority trial done at 15 tertiary hospitals across eight regions of Spain. Eligible participants were presumptively healthy and aged between 50 years and 69 years without a personal history of colorectal cancer, adenoma or inflammatory bowel disease, family history of hereditary or familial colorectal cancer (ie, two or more first-degree relatives with colorectal cancer or one diagnosed before age 60 years), severe comorbidities, or previous colectomy. Participants were randomly assigned (1:1) to one-time colonoscopy or biennial faecal immunochemical test before invitation to screening. The primary endpoint was colorectal cancer mortality at 10 years, assessed in the intention-to-screen population. An absolute difference of less than 0·16 percentage points was required to show non-inferiority. This trial was registered with ClinicalTrials.gov, NCT00906997. Findings: Between June 1, 2009, and Dec 31, 2021, 57 404 individuals were randomly assigned to receive an invitation for colonoscopy (n=28 708) or the faecal immunochemical test (n=28 696). The intention-to-screen population consisted of 26 332 individuals in the colonoscopy group and 26 719 in the faecal immunochemical test group. In the intention-to-screen population, participation in any form of screening was 31·8% in the colonoscopy group and 39·9% in the faecal immunochemical test group (risk ratio [RR] 0·79 [95% CI 0·77 to 0·82]). Faecal immunochemical testing was non-inferior to colonoscopy with regard to the risk of colorectal cancer mortality at 10 years: the risk was 0·22% (55 deaths) in the colonoscopy group and 0·24% (60 deaths) in the faecal immunochemical test group (risk difference -0·02 [95% CI -0·10 to 0·06; RR 0·92 [95% CI 0·64 to 1·32]; pnon-inferiority=0·0005). Interpretation: Participation in screening was higher among individuals invited to faecal immunochemical test screening than colonoscopy screening. On the basis of participation observed in this study, a faecal immunochemical test-based programme was non-inferior to a colonoscopy-based programme for colorectal cancer-related mortality.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Sex‐ and Age‐Stratified Outcomes of Colonoscopy Versus Faecal Immunochemical Testing: Post‐Analysis of the COLONPREV Study

  • Castells, Antoni
  • Quintero, Enrique
  • Serra-Burriel, Miquel
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Cubiella, Joaquín
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Ono, Akiko
  • Coll-Vinent, Blanca
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
Background. Colorectal cancer (CRC) screening is effective and cost-effective in average-risk individuals. The COLONPREV study recently showed that individuals invited to a faecal immunochemical test (FIT) were more likely to participate in screening than those invited to colonoscopy, and that FIT-based screening was non-inferior to colonoscopy with respect to CRC-related mortality and CRC incidence. Objective. To assess whether the outcomes of colonoscopy- and FIT-based screening differ according to sex and age in the invited population. Methods. Presumptively healthy men and women aged 50–69 years were randomised to either a one-time screening colonoscopy or biennial FIT. In this analysis, we report participation and crossover rates, CRC-related mortality, CRC incidence, all-cause mortality, and diagnostic yield for both screening strategies, stratified by sex and by age group (50–59 and 60–69 years). Results. The eligible population consisted of 26,332 individuals assigned to colonoscopy and 26,719 assigned to FIT. As expected, participation and crossover rates were higher in women than in men and in older individuals compared with younger individuals. Participation was also consistently higher in those invited to FIT screening than in those assigned to colonoscopy across both sexes and age groups. The observed reductions in CRC-related mortality and CRC incidence, which were consistent across both screening strategies, were independent of sex or age. However, CRC-related mortality, all-cause mortality, and CRC incidence remained higher in men and older participants than in women and younger participants. Colonoscopy screening showed a higher diagnostic yield of premalignant precursor lesions across all demographic subgroups. Conclusion. Participation and reductions in CRC-related mortality and incidence were consistent across sex and age groups for both FIT- and colonoscopy-based screening strategies. The higher baseline risk observed in men could not be fully mitigated by screening. Trial Registration. ClinicalTrials.gov: NCT00906997
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Colonoscopy versus biennial FIT screening: a post hoc sustained-strategy analysis of the COLONPREV Trial

  • Castells, Antoni
  • Quintero, Enrique
  • Chen, Hongruyu
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Cubiella, Joaquín
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Ono, Akiko
  • Serra-Burriel, Miquel
Background Pragmatic colorectal cancer (CRC) screening trials compare colonoscopy with faecal immunochemical testing (FIT), but differences in adherence complicate interpretation of comparative outcomes. Objective To compare 10-year risks of CRC mortality, CRC incidence and all-cause mortality under one-time colonoscopy versus sustained FIT strategies in the COLONPREV Trial. Design We conducted a post hoc per-protocol analysis of 17 270 screening initiators aged 50–69 years in eight Spanish regions, using inverse probability weighting to adjust for observed confounding and informative protocol deviations. Results Weighted 10-year risks were similar for CRC incidence (0.80% FIT vs 0.86% colonoscopy; risk difference (RD) 0.06%, 95% CI −0.25% to 0.37%) and all-cause mortality (4.02% vs 4.09%; RD 0.07%, 95% CI −0.76% to 0.84%). CRC mortality was lower with colonoscopy (0.072% FIT vs 0.042% colonoscopy; RD −0.03%, 95% CI −0.12% to 0.06%), but estimates were imprecise. Conclusion Background Pragmatic colorectal cancer (CRC) screening trials compare colonoscopy with faecal immunochemical testing (FIT), but differences in adherence complicate interpretation of comparative outcomes. Objective To compare 10-year risks of CRC mortality, CRC incidence and all-cause mortality under one-time colonoscopy versus sustained FIT strategies in the COLONPREV Trial. Design We conducted a post hoc per-protocol analysis of 17 270 screening initiators aged 50–69 years in eight Spanish regions, using inverse probability weighting to adjust for observed confounding and informative protocol deviations. Results Weighted 10-year risks were similar for CRC incidence (0.80% FIT vs 0.86% colonoscopy; risk difference (RD) 0.06%, 95% CI −0.25% to 0.37%) and all-cause mortality (4.02% vs 4.09%; RD 0.07%, 95% CI −0.76% to 0.84%). CRC mortality was lower with colonoscopy (0.072% FIT vs 0.042% colonoscopy; RD −0.03%, 95% CI −0.12% to 0.06%), but estimates were imprecise. Conclusion Sustained colonoscopy and FIT showed similar 10-year outcomes overall, highlighting the importance of adherence pathways in pragmatic screening trials.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Long‐Term Colorectal Cancer Incidence After Adenoma and Serrated Polyp Removal: Results From the Colonprev Trial

  • Cubiella, Joaquín
  • García-Benito, Carme
  • Castells, Antoni
  • Quintero, Enrique
  • Bujanda, Luis
  • Castán-Cameo, Susana
  • Díaz-Tasende, José
  • Lanas, Ángel
  • Ono, Akiko
  • Frías-Arrocha, Eladio
  • Hernández, Cristina
  • Jover, Rodrigo
  • Andreu, Montserrat
  • Carballo, Fernando
  • Morillas, Juan Diego
  • Salas, Dolores
  • Regueiro-Expósito, Cristina
  • Davila-Piñón, Pedro
  • Diez-Martín, Astrid
Background: The risk of colorectal cancer (CRC) after serrated polyp resection remains unclear, and current surveillance recommendations rely on limited evidence. We evaluated CRC incidence in individuals with advanced serrated lesions (ASL) detected at baseline colonoscopy and compared risk according to the most advanced lesion identified. Methods: Participants undergoing colonoscopy within the COLONPREV trial (n = 8989) were included in this post hoc analysis. Individuals were classified according to the most advanced baseline lesion: no lesion, non-advanced adenoma, advanced adenoma, or ASL. The primary outcome was incident CRC. Cumulative incidence and hazard ratios (HR) were estimated using Cox proportional hazard models. Results: At baseline colonoscopy, serrated polyps were detected in 19.8% of participants, including ASL in 2.5%. Over a mean follow-up of 9.5 years, 44 CRC cases were diagnosed (cumulative incidence 0.49%; incidence rate 0.52 per 1000 person-years). The 10-year cumulative incidence was 0.27% in individuals without baseline lesions (n = 5496), 0.57% in those with non-advanced adenomas (n = 2091), 1.23% in advanced adenomas (n = 1218), and 1.09% in ASL (n = 184). In multivariable analysis, CRC risk was increased for non-advanced adenomas (HR 3.25, 95% CI 1.48–7.16), advanced adenomas (HR 9.77, 95% CI 4.24–22.50), and ASL (HR 6.37, 95% CI 1.42–28.54). Surveillance colonoscopy was associated with lower CRC incidence (HR 0.46, 95% CI 0.22–0.95 for one colonoscopy; HR 0.09, 95% CI 0.02–0.40 for ≥ 2 colonoscopies). Conclusion: In this screening cohort, ASL were associated with increased CRC risk in the range of advanced adenomas. These findings provide risk estimates relevant to post-polypectomy management.